Melanoma/Skin Cancer News

A new clinic at The Ohio State University — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and Pelotonia Institute for Immuno-Oncology seeks to minimize the autoimmune effects of immunotherapy cancer treatment.

Jeffrey M. Farma, MD, FACS, has been appointed chair of surgery at Fox Chase Cancer Center.

CHICAGO — Combining an mRNA-based cancer vaccine with standard-of-care pembrolizumab significantly improved RFS and distant metastasis-free survival among patients with resected high-risk melanoma, study results showed.

New evidence suggests that a novel, benign nail finding may facilitate the detection of BRCA1-associated protein tumor predisposition syndrome which leaves patients at risk for certain cancers, according to a study.

The FDA has granted breakthrough device designation to VIO Skin Platform, an AI-powered tool that evaluates suspicious lesions for skin cancer, Enspectra Health announced in a press release.

CHICAGO — Individuals with resectable stage III melanoma derived significant EFS benefits with neoadjuvant immunotherapy compared with standard treatment, results from a randomized phase 3 trial presented at ASCO Annual Meeting showed.

CHICAGO — A front-line treatment regimen including lifileucel and pembrolizumab produced ongoing durable responses in some patients with unresectable or metastatic melanoma, according to findings presented at ASCO Annual Meeting.

CHICAGO — Sequencing encorafenib plus binimetinib with nivolumab and ipilimumab did not delay disease progression in adults with advanced BRAF-mutated melanoma, results from a randomized phase 2 trial showed.

CHICAGO — Adjuvant dabrafenib plus trametinib reduced mortality risk for adults with resected stage III BRAF V600-mutant melanoma, according to final results of the randomized phase 3 COMBI-AD trial.

Participation in cancer-related clinical trials could increase dramatically if researchers screened and recruited individuals using routine care patient-reported outcomes, according to results published in JAMA Oncology.